Key result
Upstream treatment with RAAS inhibitors, statins, and omega-3 fatty acids lacks sufficient evidence to justify broad recommendations for the primary prevention of atrial fibrillation.
Why the study?
Does upstream treatment (RAAS inhibitors, statins, omega-3 fatty acids) prevent the incidence of atrial fibrillation in patients with AF risk factors?
Does upstream treatment (RAAS inhibitors, statins, omega-3 fatty acids) prevent the incidence of atrial fibrillation in patients with AF risk factors?
Upstream treatments like RAAS inhibitors and statins show potential for AF prevention, but current evidence is insufficient for broad clinical recommendations.
Supports restraint from routine upstream therapy for AF prevention; leaves open efficacy pending targeted RCTs.
Inhibitors of the renin-angiotensin-aldosterone system, statins, and possibly , ω-3 polyunsaturated fatty acids may influence the incidence of atrial fibrillation (AF), and can be used to prevent it. In recent medical literature, this approach is referred to as upstream treatment. The results of experiments and clinical studies show that the use of these drugs may be useful for AF primary prevention in certain categories of patients. Nevertheless, there are currently no sufficient evidences to justify these recommendations and apply them to a wider range of patients with AF risk factors. Thus, it is reasonable to continue studies on both primary and secondary AF prevention.
No takes yet. Share an insight, caveat, or question.
Протасова et al. (2012) conducted a review in Atrial fibrillation. Inhibitors of the renin-angiotensin-aldosterone system, statins, and ω-3 polyunsaturated fatty acids was evaluated on Incidence of atrial fibrillation. Upstream treatment with RAAS inhibitors, statins, and omega-3 fatty acids lacks sufficient evidence to justify broad recommendations for the primary prevention of atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: